Yes, acyclovir is just as effective as Valtrex (valacyclovir) for treating herpes simplex infections.
Both acyclovir and valacyclovir are comparable in clinical outcomes for treating and suppressing herpes simplex virus infections 1. The key difference lies in dosing convenience, not efficacy.
Clinical Efficacy Evidence
The CDC guidelines explicitly state that "valacyclovir and famciclovir are comparable to acyclovir in clinical outcome" 1. This equivalence has been demonstrated across multiple treatment scenarios:
For Episodic Treatment of Recurrent Genital Herpes
Both medications are listed as equally acceptable options 1:
- Acyclovir: 400 mg three times daily OR 200 mg five times daily OR 800 mg twice daily for 5 days
- Valacyclovir: 500 mg twice daily for 5 days
Multiple randomized controlled trials confirm this equivalence. A 1998 study of 1,200 patients found no significant difference between valacyclovir 1000 mg twice daily and acyclovir 200 mg five times daily in resolution of symptoms (median 4.8 days for both), lesion healing, pain duration, or viral shedding 2. Similarly, a 2004 crossover trial showed both drugs equally suppressed HSV shedding with no significant differences in frequency or quantity of viral detection 3.
For Suppressive Therapy
Both are equally effective at reducing recurrence frequency by ≥75% in patients with frequent recurrences 1:
- Acyclovir: 400 mg twice daily (with documented safety for up to 6 years)
- Valacyclovir: 250 mg twice daily, 500 mg once daily, or 1000 mg once daily
A 2007 pilot study specifically comparing suppressive therapy found identical recurrence rates of 23.1% in both the valacyclovir (500 mg daily) and acyclovir (400 mg twice daily) groups over 12 months 4.
For First-Episode Genital Herpes
A multicenter trial of 643 patients demonstrated that valacyclovir 1000 mg twice daily and acyclovir 200 mg five times daily were equivalent in duration of viral shedding, time to healing, and pain duration 5.
The Real Difference: Pharmacokinetics and Convenience
Valacyclovir is simply the prodrug of acyclovir 6, 7. After oral administration, valacyclovir is rapidly converted to acyclovir in the body, achieving 3-5 times higher bioavailability than oral acyclovir 5. This superior absorption allows for:
- Less frequent dosing (twice daily vs. 3-5 times daily for acyclovir)
- Improved compliance due to convenience 1
- Same active drug (acyclovir) ultimately doing the work
The guidelines acknowledge that "valacyclovir and famciclovir may provide increased ease in administration, which is an important consideration for prolonged treatment" 1.
Important Caveats
Dosing Exception
One valacyclovir regimen is less effective: 500 mg once daily appears inferior in patients with very frequent recurrences (≥10 episodes per year) 1. In these patients, use higher valacyclovir doses or standard acyclovir dosing.
Long-term Safety Data
Acyclovir has more extensive long-term safety documentation (up to 6 years), while valacyclovir data at the time of older guidelines was limited to 1 year 1. However, since valacyclovir converts to acyclovir, this distinction is largely academic.
HIV-Infected Patients
Both drugs remain equally effective in HIV-infected individuals. A study of 1,062 HIV-positive patients found valacyclovir 500 mg twice daily and acyclovir equally effective for suppression 8.
Practical Recommendation
Choose based on convenience and cost, not efficacy:
- If dosing frequency matters (compliance concerns, patient preference): Valacyclovir twice daily
- If cost is the primary concern: Acyclovir (typically less expensive as generic)
- If patient has ≥10 recurrences yearly: Avoid valacyclovir 500 mg once daily; use higher doses or acyclovir
Both medications have comparable adverse event profiles, with nausea and headache being the most common side effects 4, 2.